针对组织因子凝结启动复合体,可以防止抗脂抗体的发展
Nadine Müller-Calleja1,2, Kristin Grunz1, T Son Nguyen1
1Center for Thrombosis and Hemostasis, Johannes Gutenberg University Medical Center, Mainz, Germany.
Blood
|December 24, 2023
概括
使用线虫抗凝蛋白c2 (NAPc2) 向组织因子 (TF) 启动复合体,可以防止抗脂抗体 (aPL) 诱导的血栓形成. 在病毒感染和狼模型中,NAPc2还抑制了aPL的发展,这表明了新的治疗策略.
科学领域:
- * 免疫学 免疫学
- * 血栓形成的原因
- * 分子生物学 * 分子生物学
背景情况:
- *抗脂抗体 (aPL) 是抗脂综合征 (APS) 中获得性血栓形成的主要原因.
- * 目前针对APS的干预措施主要集中在抗凝剂上,防止自身免疫性aPL发展的需求尚未得到满足.
- * 脂质反应性aPL识别了内皮蛋白C受体呈现的lysobisphosphatidic酸,激活了TF-依赖的原血栓信号传递.
研究的目的:
- * 为了研究抑制组织因子 (TF) 凝血启动复合体与线虫抗凝蛋白c2 (NAPc2) 的治疗潜力.
- * 探索TF和NADPH氧化酶在aPL发育中的作用以及相关的前血栓效应.
- * 在临床前模型中评估NAPC2在预防aPL诱导的血栓和炎症方面的疗效.
主要方法:
- *向患有COVID-19衍生的aPL或实验诱导的APS的小鼠给予NAPC2.
- *评估单细胞激活,反应性氧物种的产生和干扰素α分泌.
- * 在小鼠细胞巨乳病毒感染和MRL-lpr狼模型中对NAPC2治疗的评估.
主要成果:
- *NAPc2抑制了COVID-19衍生的aPL和aPL诱导的单细胞激活的原血栓效应.
- *NAPc2抑制了细胞质域依赖的TF反应性氧物种的产生和干扰素α分泌.
- * 短期的NAPC2干预预防了潜伏病毒感染期间持续的aPL发展.
- * 在MRL-lpr小鼠中,NAPC2治疗减弱了狼病理,树突细胞激活和aPL产生.
结论:
- * 一种趋同的TF-依赖机制是病毒感染和自身免疫性疾病中aPL发展的基础.
- * 通过NAPc2对TF启动复合物的特异性抑制证明了除了抗凝作用之外的治疗益处.
- * 针对TF启动复合体是一个有希望的策略,可以预防aPL的发展和相关的病理.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
706
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
706
Clot Retraction and Fibrinolysis
6.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.1K
Extrinsic and Intrinsic Pathways of Hemostasis
7.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.9K
Coagulation
6.8K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
526
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
526
Formation of the Platelet Plug
6.4K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.4K


